Literature DB >> 12351412

PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors.

Saverio Minucci1, Silvia Monestiroli, Sabrina Giavara, Simona Ronzoni, Francesco Marchesi, Alessandra Insinga, Daniela Diverio, Patrizia Gasparini, Manuela Capillo, Emanuela Colombo, Cristian Matteucci, Francesco Contegno, Francesco Lo-Coco, Eugenio Scanziani, Alberto Gobbi, Pier Giuseppe Pelicci.   

Abstract

Acute promyelocytic leukemia (APL) is associated with chromosomal translocations resulting in fusion proteins of the retinoic acid receptor (RAR). Here, we report a novel murine model system for APL, based on the transduction of purified murine hematopoietic progenitors (lin(-)) using high-titer retroviral vectors encoding promyelocytic leukemia-RAR (PML-RAR), and the green fluorescent protein (GFP) as a marker. PML-RAR-expressing lin(-) cells were impaired in their ability to undergo terminal myeloid differentiation and showed increased proliferative potential in vitro. Inoculation of transduced lin(-) cells into syngeneic, irradiated mice resulted in the development of retinoic acid-sensitive promyelocytic leukemias at high frequency (> 80%) and short latency (approximately 4 months). Morphologic and immunophenotypic analysis revealed no gross abnormalities of the preleukemic bone marrows. However, hematopoietic progenitors from PML-RAR preleukemic mice showed a severe impairment in their ability to undergo myeloid differentiation in vitro. This result, together with the monoclonality or oligoclonality of the leukemic blasts, supports a "multiple-hit" model, where the fusion protein causes a "preleukemic" phase, and leukemia occurs after additional genetic lesions. This model system faithfully reproduces the main characteristics of human APL and represents a versatile tool for the in vitro and in vivo study of mechanisms of leukemogenesis and the design of protocols for differentiation treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351412     DOI: 10.1182/blood-2001-11-0089

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

2.  Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue.

Authors:  Mirco Fanelli; Stefano Amatori; Iros Barozzi; Saverio Minucci
Journal:  Nat Protoc       Date:  2011-11-10       Impact factor: 13.491

3.  Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples.

Authors:  Mirco Fanelli; Stefano Amatori; Iros Barozzi; Matias Soncini; Roberto Dal Zuffo; Gabriele Bucci; Maria Capra; Micaela Quarto; Gaetano Ivan Dellino; Ciro Mercurio; Myriam Alcalay; Giuseppe Viale; Pier Giuseppe Pelicci; Saverio Minucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-24       Impact factor: 11.205

4.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

5.  Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.

Authors:  Serena Racanicchi; Chiara Maccherani; Concetta Liberatore; Monia Billi; Vania Gelmetti; Maddalena Panigada; Giovanni Rizzo; Clara Nervi; Francesco Grignani
Journal:  EMBO J       Date:  2005-02-24       Impact factor: 11.598

6.  FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors:  Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

7.  Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.

Authors:  Julien Ablain; Kim Rice; Hassane Soilihi; Aurélien de Reynies; Saverio Minucci; Hugues de Thé
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

Review 8.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

9.  The PML domain of PML-RARα blocks senescence to promote leukemia.

Authors:  Katharina Korf; Harald Wodrich; Alexander Haschke; Corinne Ocampo; Lena Harder; Friederike Gieseke; Annika Pollmann; Kevin Dierck; Sebastian Prall; Hannah Staege; Hui Ma; Martin A Horstmann; Ronald M Evans; Thomas Sternsdorf
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

10.  PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia.

Authors:  Christopher B Cole; Angela M Verdoni; Shamika Ketkar; Elizabeth R Leight; David A Russler-Germain; Tamara L Lamprecht; Ryan T Demeter; Vincent Magrini; Timothy J Ley
Journal:  J Clin Invest       Date:  2015-11-23       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.